Business
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Reported positive results from the Phase 2b/3 PRISM trial of Haduvio™ in the treatment of Prurigo Nodularis Completed a $55 million private placement Data
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Reported positive results from the Phase 2b/3 PRISM trial of Haduvio™ in the treatment of Prurigo Nodularis\nCompleted a $55 million private placement\nData from the full set of subjects in the completed Phase 2 CANAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) expected in the third quarter of 2022\nManagement to host a conference call and webcast today at 4:30 p.m. EDT\nNEW HAVEN, Conn., Aug. 11, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended June 30, 2022, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nTrevi’s topline data expected for Ph2b/3 PRISM study this quarter and full results for Ph2 CANAL study in Q3\"The positive trial results reported this quarter in the treatment of prurigo nodularis not only further support the continued development of Haduvio in another therapeutic indication with a high unmet need, but also reaffirms the mechanism of action and the importance of having both a peripheral and centrally active therapy,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"As a next step in our prurigo nodularis program, we plan to request an end of phase 2 meeting with the FDA. In our chronic cough in IPF program, we are looking forward to providing topline efficacy and safety data on the full set of subjects enrolled in the completed Phase 2 CANAL study this quarter. We are actively preparing for the next trial in chronic cough in IPF and are looking forward to discussing the program and trial plan with the FDA at a meeting scheduled for this quarter.\"\nKey Business Updates\nPhase 2b/3 PRISM trial of Haduvio in the treatment of Prurigo Nodularis \nAs previously announced in the Phase 2b/3 PRISM trial, results comparing subjects randomized to Haduvio (n=168) or placebo (n=176) achieved the primary and two key secondary endpoints. In addition, the Company has received the analysis on the final key secondary endpoint, the PROMIS sleep scale, which also achieved that endpoint with statistical significance at week 14. Below is a summary of the primary and all key secondary endpoints:\n25...